

August 11, 2026

Dear colleague,

We are writing to share a difficult benefits decision that will affect health system insurance coverage for GLP-1 medications under our employee medical plan next year.

Beginning Jan. 1, 2027, GLP-1 medications will be covered only for those who have a confirmed diagnosis of Type 2 diabetes. GLP-1 medications prescribed for any other diagnosis or purpose will no longer be covered.

Transition support is available

To assist you, our benefits and pharmacy teams have created a support toolkit at **KansasHealthSystemBenefits.com/GLP-1**. This transition web page brings together practical information to help you understand your options and, together with your prescriber, have a plan in place well before Jan. 1. You will find questions to ask your physician, information about covered alternatives when appropriate and several other resources.

Details and all our support resources related to the change are available by scanning the QR code below.



KansasHealthSystemBenefits.com/GLP-1

This online toolkit also includes information about manufacturer savings programs. Today, manufacturers offer direct-to-consumer pricing for GLP-1 medications that is substantially lower than the price they charge our employee medical plan for those same medications.

In addition to the toolkit, our benefits specialists are available for one-on-one meetings. They can help you understand your plan coverage, HSA/FSA considerations and the transition resources available to you. To schedule, visit the website above.

Why this change is necessary

When these medications became available, we chose to cover them because we recognized their potential to improve health for many employees and family members. We maintained this coverage for all diagnoses while many employers reduced or eliminated it because we hoped the marketplace would evolve toward a long-term solution more affordable for the health system. Unfortunately, that has not happened.

We made this decision after carefully considering how to keep health insurance affordable for the 30,000 employees and family members covered by our medical plan. Without a change, the growing cost of GLP-1 use for diagnoses other than Type 2 diabetes would require substantial premium increases for every employee covered by our medical plans, whether or not they take a GLP-1 medication. Our responsibility to protect the affordability of our employee medical plan for everyone who depends on it requires us to make this change.

-- turn page over --

Why we are sharing this now

In addition to employees and family members already taking these medications, we know many may be considering GLP-1 treatment. Many more may receive new prescriptions between now and the new year.

We are announcing this change now so affected members have time to talk with their physicians, review financial options and consider the impact before annual benefits enrollment in October.

What affected members should do now

If you or a covered family member currently take a GLP-1 medication for a diagnosis other than Type 2 diabetes, we encourage you to begin talking with your physician or other prescribing clinician now and no later than Dec. 1. This will give you time to review your options and make a plan before your last covered refill.

Your physician or prescribing clinician is the best source for guidance about your health and medication options. Please do not stop taking any medication without talking with them.

If your prescribing physician is within our health system, contact their office through MyChart by sending a message. This will help clinic teams respond efficiently and route your question appropriately.

Next steps

We remain hopeful that advances in the marketplace or science will improve the affordability of GLP-1 medications over time. As we do with all employee benefits and prescription drug coverage, we will continue to monitor costs and evaluate coverage decisions as the marketplace evolves.

We encourage you to use the resources available at ***[KansasHealthSystemBenefits.com/GLP-1](https://www.kansashealthsystem.com/benefits/GLP-1)***.

We are committed to helping you understand your options and supporting you through this transition.

Sincerely,

Tammy Peterman, MS, RN, FAAN

President, Chief Operating Officer and
Chief Nursing Officer

Steven Stites, MD

Executive Vice President - Clinical Affairs
Chief Medical Officer

Jeff Risinger, PhD

Senior Vice President,
Chief Human Resources Officer